{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-056866","form_type":"8-K","ticker":"INAB","cik":"0001740279","company_name":"IN8BIO, INC.","filed_at":"2024-05-09T23:59:59+00:00","discovered_at":"2026-05-14T18:03:19.840855+00:00","generated_at":"2026-06-02T06:33:19.070601+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"IN8bio reports Q1 2024 net loss $8.6M, cash $13.0M; first patient dosed in INB-400 Phase 2","bullets":["Q1 net loss $8.6M ($0.20/sh) vs $7.5M ($0.30/sh) in Q1 2023; R&D $4.9M, G&A $3.7M.","Cash $13.0M at March 31, 2024, down from $21.3M at December 31, 2023.","First patient dosed in Phase 2 autologous arm of INB-400 for newly diagnosed GBM.","Potential IND submission for INB-100 Phase 2 registrational trial in 2024 in AML/MDS.","Preclinical nsCAR data at AACR 2024 targeting CD33/CD123 for AML while sparing healthy cells."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-056866","json":"https://secwatch.observer/filing/0000950170-24-056866.json","markdown":"https://secwatch.observer/filing/0000950170-24-056866.md","text":"https://secwatch.observer/filing/0000950170-24-056866.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1740279/000095017024056866/0000950170-24-056866-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1740279/000095017024056866/inab-20240509.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-02T06:33:19.070601+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}